Genentech’s Lucentis BLA Will Not Include Data Supporting Dosing Advantage
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's decision to deny Genentech fast-track status for Lucentis (ranibizumab) means that the initial submission for the wet age-related macular degeneration therapy, slated for December, will not include data supporting a dosing advantage
You may also be interested in...
Retaane “Approvable” For Macular Degeneration; Alcon Plans July Meeting With FDA
Alcon expects to meet with FDA in July to discuss a May 23 "approvable" letter for its wet age-related macular degeneration agent Retaane (anecortave acetate suspension)
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product